Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug
https://www.biospace.com/article/releases/telomir-pharmaceuticals-unveils-compelling-pre-clinical-data-on-age-reversal-drug-telomir-1-at-national-press-club-event-in-washington-d-c-/
Question: Is Telomir-1 the successor of MYMD-1, discovered by the same people, who are now running Telomir Pharmaceuticals?
Have MYMD investors been totally abandoned while the best discoveries have been homed in a new company?
An unpleasant question to ask. I hope to be proven wrong.
From the 8-K just filed: https://ir.mymd.com/sec-filings/all-sec-filings##document-1028-0001493152-24-013870-1
Bio of Dr. Mitchell Glass (from https://www.medproinvestors.com/team; out of date probably)
Dr. Mitchell Glass is a 25 year veteran of the pharmaceutical industry.
His experience includes senior positions at top ten pharmaceutical companies,
as well as investment in and management of start-ups and biotechs.
After seven years of research, teaching and patient care at the University of Pennsylvania, Dr. Glass joined ICI Pharmaceuticals in 1988 where he established the pulmonary therapeutics group and led the development and submission of the antileukotriene ACCOLATE®. From 1995 to 1996, Dr. Glass was Vice President and Director at SmithKline Beecham where he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialization, including submission of the NDA/MAA for COREG®. From 1998 to 2003, Dr. Glass was Chief Medical Officer and VP of Clinical Development and Regulatory Affairs of AtheroGenics Inc. (AGIX), where he led product development from IND to initiation of Phase 3 for AGI1067 and was a member of the IPO team. Dr. Glass later joined AQUMEN Biopharmaceuticals KK and NA as CEO of AQUMEN NA and currently serves as Executive VP R&D and Chief Medical Officer of Invion Limited. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.
***
I have no idea what any of this 8-K signifies. Maybe tells us some preferred stock can be converted to common on terms specified in subsidiary documents.
Previous msg posted twice. No idea why.
I've noticed that migration. I wonder if the Telomir drug is a direct descendent of MYMD-1. If so, it seems that it should have been kept in MYMD for the benefit of MYMD's investors. Is it the case that they came up with something of extraordinary potential and decided to move it out of MYMD, abandoning the investors there, and put it into a new company to benefit a new group of investors? I hope this is not what's going on, but in the absence of communication from the company we can have no idea.
Canadian patent 3013634 granted
Abstract: "In one aspect, a method of increasing hair growth includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle therefor. In another aspect, a method of improving the appearance of hair includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor."
isomyosmine (MYMD-1) is interestingly versatile.
Near the close the price went as high as 0.21 on over 3,200,000 shares, then collapsed to 0.17 on much lower volume, closing at 0.203. After hours 0.18 seems to be popular. Hair raising, if you care. I don't much. This announcement means little, far as I can tell.
I don't know about Ray Blanco's current list. Read something by him many months ago. He was right then, and still right now about the science. But badly wrong about a good time to buy.
I don't agree. My friends, employees, and I had direct experience with Anatabloc, a product of William's Star Scientific. The anatabine-citrate molecule was the real thing. The benefits were remarkable. People homebound with Crohn's disease were set free.
Now, there is evidence that the isomyosmine molecule, MYMD-1, is an improvement on anatabine-citrate.
The article linked should be treated with suspicion as a possible "hit piece". There were political currents involving Bob McDonnell's race for governor of Virginia. Williams got swept up in those currents and a letter was issued by the FDA (trust them? no) that destroyed his company and injured McDonnell.
The molecule being developed by Williams and his collaborators at Johns Hopkins is both a threat and an opportunity for major pharma companies currently earning large revenues from the sale of biologics.
MYMD-1 does everything the leading biologics (Enbrel, Humira) do, but better and without the serious side effects. They are biological sledge hammers, MYMD-1 is a jewelers hammer.
Ray Blanco's assessment is correct.
Science Direct article about isomyosmine, 2019
A four year old article about the molecule that is MYMD-1
https://www.sciencedirect.com/science/article/abs/pii/S0165572819302206
Abstract
Multiple sclerosis (MS) is an autoimmune disease that remains in need of effective therapies. Plant-derived medicines have appealing properties for the treatment of autoimmune diseases. MYMD-1 is a synthetic plant alkaloid that has been shown to ameliorate the course of autoimmune thyroiditis. The goal of the present study was to determine whether MYMD-1 would produce similar beneficial effects in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE) induced by immunization with myelin oligodendrocyte glycoprotein. MYMD-1 improved the course of EAE and suppressed activation of effector T cells without causing global immunosuppression or toxicity. These results suggest that MYMD-1 may be of interest for evaluating for the treatment of autoimmune diseases.
Jonnie R Williams, MyMD: A patent of astonishing range just allowed
https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20220339147
In paragraph [0012] note the breadth of coverage - far beyond "visual system"
Patent Application Publication ao) Pub. No.: US 2022/0339147 Al
Williams Pub. Date: Oct. 27,2022
METHOD OF TREATING DISEASES OF THE VISUAL SYSTEM
SUMMARY
[0009] In some aspects, a method of regulating oxidoreductase activity for treating an inflammation or age-related disorder comprises administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor. In some examples, the inflammation-related disorder is a parasitic infection or disease such as malaria. In other examples, the inflammation-related disorder is a bacterial infection or disease such as Lyme disease.
[0010] In other examples, a method of treating oxidative stress associated with an inflammation or age-related disorder comprises administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.
[0011] In yet other examples, a method of reducing oxidative stress in an individual suffering from an inflammation or age-related disorder comprises administering to the individual a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.
[0012] In other aspects, a method of treating a disorder comprises administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, where the disorder is selected from the group consisting of infectious or parasitic diseases; neoplasms; diseases of the blood or blood-forming organs; diseases of the immune system; endocrine; nutritional or metabolic diseases; mental, behavioral or neurodevelopmental disorders; sleep-wake disorders; diseases of the nervous system; diseases of the visual system; diseases of the ear or mastoid process; diseases of the circulatory system; diseases of the respiratory system; diseases of the digestive system; diseases of the skin; diseases of the musculoskeletal system or connective tissue; diseases of the genitourinary system; conditions related to sexual health; pregnancy, childbirth or the puerperium; conditions originating in the perinatal period; developmental anomalies; and injury ,poisoning or other consequences of external causes. In one example, a behavioral or neurodevelopmental disorder is anxiety. In another example, a behavioral or neurodevelopmental disorder is depression.
***
A closely related patent:
Patent Application Publication (io)Pub. No.: US 2020/0338061 Al
Jonnie R Williams Pub.Date: Oct. 29,2020
METHODS OF REGULATING OXIDOREDUCTASE ACTIVITY FOR
TREATMENT OF INFLAMMATION AND AGE-RELATED DISORDERS
Applicant: MyMD Pharmaceuticals, Inc., Tampa, FL (US)
Entirely accidental. Making minor edits. I intended one post. Hub decided to make two posts. No idea why.
No idea why post #394 was posted by iHUBs software.
The correct version of the post (almost identical) is post #393, which I edited a few times.
Then iHUB decided to post the unedited version as #394.
Sometimes stock price is based on incomplete information.
Take a look at what happened to Tempest Pharmaceuticals (TPST) on 11 Oct 2023.
Information previously unknown to market participants became known. On that day the stock opened at $0.17, moved up on wild speculation to $9.80, and closed at $3.60. Its current price is $3.76.
A stock chart will show a pattern of steady decline that resembles what we are seeing for MYMD.
But, nothing about TPST can be taken to predict anything about the future of MYMD.
TPST does illustrate that sudden introduction of new information can have a radical effect on stock price.
Such may happen with MYMD. My understanding of the science suggests to me that it's possible. Ray may have his day.
Sometimes stock price is based on incomplete information.
Take a look at what happened to Tempest Pharmaceuticals (TPST) on 11 Oct 2023.
Information previously unknown to market participants became known. On that day the stock opened at $0.17, moved up on wild speculation to $9.80, and closed at $3.60. Its current price is $3.76.
A stock chart will show a pattern of steady decline that resembles what we are seeing for MYMD.
But, nothing about TPST can be taken to predict anything about the future of MYMD.
TPST does illustrate that sudden introduction of new information can have a radical effect on stock price.
Such may happen with MYMD. My understanding of the science suggests to me that it's possible.
Ray Blanco may have his day.
Ray Blanco is correct about the science. Credible results from trials can make that clear, and I think they will do that. However, the quality of business strategy is not something I can judge.
Last trade of the day: 1,387,425 shares.
The link you posted leads to something good - not obvious from the url only:
"Revolutionizing Autoimmune Medicine: MyMD Pharmaceuticals Innovative Therapies
BioTalk with Rich Bendis"
https://podcasts.apple.com/us/podcast/revolutionizing-autoimmune-medicine-mymd-pharmaceuticals/id1274273731
Thanks!
Wobs — thanks for the links - those interviews are interesting.
News Release Today
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
https://ir.mymd.com/news-events/press-releases/detail/54/mymd-announces-preclinical-study-results-showing-novel
PR: new data on Potential TNF-a Market Disrupter
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023
https://www.businesswire.com/news/home/20231004139695/en/
PR This morning: Positive Sarcopenia Results
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-a Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
https://www.benzinga.com/pressreleases/23/07/b33469123/mymd-pharmaceuticals-reports-statistically-significant-positive-topline-phase-2-results-for-next-g
Hi Ray Blanco - expecting to hear from you!
[trading halted until 9:50 am]
SEC filing today: "MyMD Pharmaceuticals Inc Awaits Receipt Of Data From Phase 2 Trial For MYMD-1"
This was in an SEC filing, an 8-K, from the company, today. The above is the entire content of the filing.
https://content.equisolve.net/sec/0001493152-23-024537/form8-k.htm
Why would they put out such a statement?
Will buy more. I think Blanco gets it right.
You are right.
I don't see an ethical problem. Incentives matter. I like companies where the people who make me wealthier have a chance to do the same for themselves.
The options cost nothing and are exercisable in five years at a stated price ($1.66).
See Table II, Column 8, where "Price of Derivative Security" is listed as $0. And the "Conversion" (exercise) price, shown in column 2 will be, five years from 06/07/23, $1.66.
If they exercise the options at that price when the stock is selling at a much higher price they will make money and they will have made money for us. Fair, as I see it.
Thanks! I probably would have missed that, and it seems significant.
New Jonnie R. Williams Patent, "Cannabinoid Compounds"
Issue Date: 4/18/23
Inventor Name: Jonnie R. Williams
Organization Name: MyMD Pharmaceuticals (Florida), Inc.
Title: Synthetic Cannabinoid Compounds for Treatment of Substance Addiction and Other Disorders
https://patentcenter.uspto.gov/applications/17383119/ifw/docs
See document "Application Data Sheet" dated 07/22/2021 for details of original filing.
Conjecture: Williams (totally without credentials) is one of the world's most important biochemists. -- to be refuted in time, or not. (See Conjectures and Refutations, by Karl R. Popper)
Looks to me like cohorts 1,2,3 are done, and a boost of dose is still ahead for cohort 4.
Ray Blanco, on 23 Feb 2023 told readers that the $15 million raise is a positive signal because it shows that current large investors have confidence in the company's progress and prospects.
I think Ray was calling his own communication an "update". As in "I'm updating my readers on what I'm thinking now."
Just got Ray Blanco's email: "An Important Update About Our Miracle Drug Play". Came in at about 10:30 ET.
Says the new drug could prove revolutionary, and that huge catalysts [to stock price, I assume] will come in the near future
Blanco's email covers the science already familiar to participants in this board, and earlier boards covering Star Scientific and Anatabloc.
Although MYMD-1 is not anatabine citrate (Star Scientific), its functions are similar, and it is being developed by some of the same scientists, behind whom stands Jonnie Williams.
For that science see https://www.mymd.com
I watch Ray Blanco and have seen nothing from him about MyMD recently. But if I've missed something please post about it. Thanks.
Anyone know anything about what's causing the sudden increase in price and volume?
Rivard Paul (EVP of Operations, GC) Buys 10,000 @ Avg Price: $1.53
https://www.benzinga.com/secfilings/22/12/30016914/mymd-pharmaceuticals-inc-rivard-paul-evp-of-operations-gc-buys-10-000-avg-price-1-53-form4
6 Dec 2022 News Release
https://www.businesswire.com/news/home/20221206005205/en/
Two important things (of many):
1) Selective inhibition of TNF-alpha
2) Oral administration
The reduction of inflammation compared to a widely prescribed biologic may not be as great as some had hoped.
What the NR does not cover is the harm not done by MYMD-1 compared to the (and all similar) biologic.
"Harm Not Done" should become a major selling point.
MYMD-1 is a jeweler's hammer, harmlessly doing only what's needed; Currently prescribed biologics are a wrecking ball, doing what's needed, but also doing a lot that's harmful.
The latest news: Conservative language reports results of significance which are poorly understood. Stronger sales language would boost the stock price. I'm happy to wait.
I don't see anything in that news release that limits the positive results to "one group". Please clarify. Thanks.
What's essentail to understand about MYMD-1
From today's announcement:
Upcoming Presentation of Late-Breaking Data for MYMD-1
https://www.businesswire.com/news/home/20221117005091/en/
Phase 2 results expected in Q4 2022
From today's news release: